MYELOMA360 is a novel insight-led community for biopharmaceutical companies and healthcare professionals centralizing information, ideas and education to address these issues. It brings independent, unbiased expertise and opinion to the community, to help improve the lives of patients living with multiple myeloma.

The treatment of multiple myeloma has never been so opportunistic, yet so complicated. With 30+ approved drugs, treatments and advanced diagnostic and prognostic testing, community clinicians are unsure about best treatment / management decisions.

Myeloma is a complicated disease to accurately diagnose and treat. Drug development in myeloma is increasingly challenging and requires expert insights to best navigate a successful development plan.